Solvemate Enables Greater Customer Inclusiveness with Enhanced Accessibility Features
23.11.2021 12:06:00 EET | Business Wire | Press release
Conversational AI for Customer Service leader Solvemate today announces the availability of improved accessibility for its customer service automation platform. Solvemate accessibility helps customer service teams extend the use of self-service to those with impairments so all customers can find instant answers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211123005628/en/
Solvemate Conversational AI for customer service helps those with impairments have meaningful conversations with automation.
Improving the Customer Service Experience for Everyone
According to the World Health Organization, over 1 billion people live with some form of disability. Inclusion is an imperative that should be built into every company’s strategy. Accessibility is also an important aspect of the service experience to drive customer satisfaction and loyalty.
Modern customer service chatbots using Artificial Intelligence (AI) already offer enhanced digital accessibility and usability. Conversational AI chatbots extract insights and patterns from data to identify and propose the most logical answers to end users. Customers then solve their problem in the fewest number of interactions. Modern chatbots offer the right knowledge at the right time in a condensed manner which helps people with cognitive disabilities in a way that an extensive FAQ page can not.
Solvemate’s customer service automation platform is now more accessible to people with sight, hearing, visual and mobility impairments. Solvemate is Web Content Accessibility Guidelines (WCAG) 2.2 compliant.
Solvemate’s enhanced accessibility features include:
-
For those with cognitive impairments:
- The Solvemate Contextual Conversation Engine™ uniquely uses both dynamic decision tree logic buttons and free text fields (NLP)
-
For those with hearing impairments:
- Solvemate’s chatbot includes text and image conversation descriptions to read along as well as a text-based handover
-
For those with mobility impairments:
- Solvemate's Conversational IVR ( voice) allows intuitive access to customers service via phone
-
For those with visual impairments:
- Solvemate widget can be fully navigated with screen readers
No Additional Work for Customer Service Teams
Solvemate’s accessibility feature works out of the box with no extra effort for the service team setting up the chatbot. Teams can instantly extend their service offering to more customers with personalized, self-service automation.
Jürgen Vogel, co-founder and CTO of Solvemate, comments: “Providing accessibility for those that need additional support is an imperative for all customer service teams. We see this across all sectors, particularly banking and public institutions that need to make services equitably available to all users.”
Read more about why chatbots are key to customer service accessibility.
Learn more at solvemate.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005628/en/
Contact information
Press Contact:
Sylvia Jensen
s.jensen@solvemate.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 16:15:00 EEST | Press release
OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leading AI providers, including Anthropic, Google, OpenAI, xAI, and DeepSeek, among others. The platform is used by over 8 million global users, including AI-native startups and large enterprises,
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 16:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in markets traditional channels can't reach. Each operates at the center of how games are discovered, adopted, an
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 15:00:00 EEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 15:00:00 EEST | Press release
ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful innovation to patients through technologies that advance precision, safety, and the overall treatment experience,” said Sheraz Daya, MD, Medical Director and Founder of Centre for Sight. “We are proud to be the first center globally
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 15:00:00 EEST | Press release
BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures and HEPATOMUNE® tri-cultures. Additionally, Christian Smith, Scientist I, R&D at BioIVT will present a poster titled "Therapeutic Reversal of Established Steatosis Usin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom